Evidence map›Paper›PMID 35548413›Full record

ReviewFrontiers in cardiovascular medicine2022

Etiology and Management of Dyslipidemia in Patients With Cancer.

Mikhail de Jesus, Turab Mohammed, Meghana Singh, John G Tiu, Agnes S Kim

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in cardiovascular medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 2 pooled it
2.7field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 2 syntheses or guidelines pooled it, 28 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Medication Induced Dyslipidemia in Children.Current atherosclerosis reports · 2025
    Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Journal of fungi (Basel, Switzerland) · 2024
    Article
  18. Article
  19. The evolving landscape of PCSK9 inhibition in cancer.European journal of pharmacology · 2023
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Mikhail de JesusDepartment of Medicine, University of Connecticut School of Medicine, Farmington, CT, United States.
Turab MohammedDepartment of Medicine, University of Connecticut School of Medicine, Farmington, CT, United States.
Meghana SinghDepartment of Medicine, University of Connecticut School of Medicine, Farmington, CT, United States.
John G TiuDepartment of Medicine, Calhoun Cardiology Center, University of Connecticut School of Medicine, Farmington, CT, United States.
Agnes S KimDepartment of Medicine, Calhoun Cardiology Center, University of Connecticut School of Medicine, Farmington, CT, United States.
University of Connecticut · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Patients with cancer are now living longer than ever before due to the growth and expansion of highly effective antineoplastic therapies. Many of these patients face additional health challenges, of which cardiovascular disease (CVD) is the leading contributor to morbidity and mortality. CVD and cancer share common biological mechanisms and risk factors, including lipid abnormalities. A better understanding of the relationship between lipid metabolism and cancer can reveal strategies for cancer prevention and CVD risk reduction. Several anticancer treatments adversely affect lipid levels, increasing triglycerides and/or LDL-cholesterol. The traditional CVD risk assessment tools do not include cancer-specific parameters and may underestimate the true long-term CVD risk in this patient population. Statins are the mainstay of therapy in both primary and secondary CVD prevention. The role of non-statin therapies, including ezetimibe, PCSK9 inhibitors, bempedoic acid and icosapent ethyl in the management of lipid disorders in patients with cancer remains largely unknown. A contemporary cancer patient needs a personalized comprehensive cardiovascular assessment, management of lipid abnormalities, and prevention of late CVD to achieve optimal overall outcomes.

Indexed as

cancercancer survivorcardiovascular risk reductioncholesteroldyslipidemia

Identifiers

PMID35548413
PMCPMC9081373
OpenAlexW4224320567

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.